Circulating tumor DNA (ctDNA) as a biomarker of response to therapy in advanced Hepatocellular carcinoma treated with Nivolumab
Authors:
Open Access
- 1 September 2024
- journal article
- research article
- Published by SAGE Publications in Cancer Biomarkers
- Vol. 41 (1) , 83-91
Abstract
BACKGROUND: Circulating tumor DNA (ctDNA) is a promising non-invasive marker for detection, diagnosis, treatment selection, and prognosis of hepatocellular carcinoma (HCC). OBJECTIVE: This study aimed to examine the utility of ctDNA as a prognostic and predictive tool in HCC patients treated with nivolumab. METHODS: We analyzed pre-treatment ctDNA from 44 HCC patients using comprehensive genomic testing on a commercially available platform. We utilized log rank test and univariate Cox models to correlate overall survival (OS) and progression-free survival (PFS) with ctDNA expressions. RESULTS: Of 44 patients, 77.3% were men with median age of 67 years. All but 3 patients had at least one alteration identified, and TP53 was the most commonly altered gene (52.3%). Median OS was 17.5 months (95% CI: 12.7, NA). Mutations involving PIK3CA , BRCA1 , and CCND1 amplification were associated with shorter OS (P 0.0001, 0.0001 and 0.01, respectively). Median PFS time was 4.01 months (95% CI: 3.06, 9.33). Mutations involving KIT and PIK3CA were associated with shorter PFS (P 0.0001 and 0.0004, respectively), while mutation involving CTNNB1 were associated with longer PFS ( p = 0.04). CONCLUSIONS: ctDNA profiling may provide a benefit for prediction of survival and progression of HCC patients treated with nivolumab. Future studies are needed for confirmation.Keywords
This publication has 21 references indexed in Scilit:
- Hepatocellular Carcinoma-Related Mortality in the USA, 1999–2018Digestive Diseases and Sciences, 2022
- Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trialThe Lancet Oncology, 2022
- Hepatocellular carcinomaNature Reviews Disease Primers, 2021
- Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With SorafenibJAMA Oncology, 2020
- Prospects and challenges of circulating tumor DNA in precision medicine of hepatocellular carcinomaClinical and Experimental Medicine, 2020
- Detection of early-stage hepatocellular carcinoma in asymptomatic HBsAg-seropositive individuals by liquid biopsyProceedings of the National Academy of Sciences, 2019
- Application of Cell-free DNA Analysis to Cancer TreatmentNew England Journal of Medicine, 2018
- Wilcoxon Rank Sum Test2013
- Fisher Exact Test2011
- Diagnosis of hepatocellular carcinomaHPB, 2005